Biosimilar Switching Studies Show No Adverse Efficacy Or Safety Effects, Researchers Say
Executive Summary
Sandoz-led review of 90 published studies finds no evidence to support theoretical concern about differences in immunogenicity when switching between reference biologics and their biosimilars; findings could instill more public confidence about biosimilars in US and reduce importance of an interchangeability designation from FDA.
You may also be interested in...
Interchangeable Biosimilars: FDA Clarifies US Reference Not Mandatory For Studies
Draft guidance strongly recommends against it, but US FDA's Leah Christl says agency is willing to talk about using foreign-licensed comparators.
Biosimilar Firms Fight Against 'Whisper Campaign' On Interchangeability
Industry calls for more education amid concerns that brand sales reps are encouraging providers to use only interchangeable products because they are better than biosimilars.
US Comparator Requirement For Interchangeable Biosimilars Would Hurt Industry
US FDA’s recommendation against use of foreign-licensed reference products in clinical switching studies would result in procurement challenges and higher costs for biosimilar developers while also limiting where such studies could be conducted, some companies say.